Table 2.
Various Salmonella strains that have been used in the combination therapy of cancer.
| Salmonella species | Type of cancer | Combine with | Anti-cancer effect | Model | Type of cell line | Ref |
|---|---|---|---|---|---|---|
| Salmonella typhimurium A1-R | Human colon cancer | Bright-light surgery (BLS) | Increase survival | Athymic nu/nu nude mice | HT-29 | (140) |
| Salmonella typhimurium A1-R | Mammary adenocarcinoma | Surgery | Inhibiting surgery-induced metastasis | Mice | 4T1-RFP | (141) |
| Salmonella typhimurium | Melanoma | γ-radiation | Apoptosis | Tumor-bearing mice | (142) | |
| Salmonella typhimurium ΔppGpp | Colon tumor | Radiotherapy | Reduced tumor growth | Colon tumor (CT26) model of BALB/c mice | CT26 | (11) |
| Salmonella ˗Lipid A | Melanomas | X-rays | Produced supra-additive antitumor effects | Mice bearing B16F10 or Cloudman S91 melanomas | B16F10 or Cloudman S91 |
(143) |
| Salmonella | Mammary tumors | Lipid A | Robust intratumoral accumulation of Salmonella | Mice with 4T1 mammary tumors | 4T1 | (144) |
| Salmonella typhimurium | Breast cancer | Low dose chemotherapy | Decreases tumor burden and less toxic | BALB-neuT mice | Her2-driven | (124) |
| Salmonella typhimurium LVR01 | Melanoma | Imiquimod | Enhancement the pro-inflammatory cytokines and chemokines | B16F1 melanoma-bearing mice | B16F1 | (145) |
| SalmonellatyphiSL7207 | Ovarian cancer | RNA interference | Slow tumor growth | SKOV-3/DDP tumor-bearing mice | SKOV-3/DDP | (45) |
| Salmonella typhimurium A1-R | Cancers | Cisplatinum (CDDP) or paclitaxel (PTX) | Prevented tumor growth | Nude mice | (146) | |
| Salmonella typhimurium A1-R | Osteosarcoma | Recombinant methioninase (rMETase) | Inhibited tumor growth | Athymic nu/nu nude mice | PDOX | (126) |
| Salmonella typhimurium A1-R | Sarcoma | Doxorubicin (DOX) | Inhibited tumor growth | Athymic nu/nu nude mice | PDOX | (147) |
| Salmonella typhimurium A1-R | Melanoma | Temozolomide (TEM) | Inhibited tumor growth | Athymic nu/nu nude mice | PDOX | (148) |
| Salmonella typhimurium A1-R | Pancreatic cancer | Anti-vascular endothelial growth factor (VEGF) therapy | Reduced tumor weight | Male athymic (nu/nu) nude mice | MiaPaCa-2-GFP | (63) |
| Salmonella typhimurium VNP20009 | Melanoma | Anti-angiogenesis therapy (triptolide | Necrosis and modulation of angiogenesis | Female C57BL/6 mice | (69) | |
| Salmonella typhimurium VNP20009 | Melanoma | (ABCB5) | Delay tumor growth | Mice | B16F10 | (132) |
| Salmonella typhimurium VNP20009 | Melanoma | Chemotherapy cyclophosphamide (CTX) | Decrease in tumor microvessel density and (VEGF) level | Murine melanoma model | (62) | |
| Salmonella typhimurium VNP20009 | Lung cancer | Sox2 shRNA | Inhibition of angiogenesis | B16F10 mice model | A549 | (137) |